GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Investments And Advances

Akeso (AKESF) Investments And Advances : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akeso Investments And Advances?

Akeso's Investments And Advances for the quarter that ended in Dec. 2024 was $0.0 Mil.


Akeso Investments And Advances Historical Data

The historical data trend for Akeso's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Investments And Advances Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial - - - - -

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akeso Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Akeso Business Description

Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in USA.